FindTrial
Sign In

To measure the concentration of potentially harmful toxic heavy metals in the blood and brain fluid of patients with ALS (amyotrophic lateral sclerosis)- a lethal neurological illness – a cross-sectional study

Estimation of concentration of neurotoxic heavy metals in plasma and cerebrospinal fluid (CSF) of patients with amyotrophic lateral sclerosis (ALS) – a cross-sectional study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/01/061645
Enrollment
60
Registered
2024-01-19
Start date
Unknown
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G122- Motor neuron disease

Interventions

Intervention1: Nil: Nil

Sponsors

Institute Research Grant AIIMS BBSR
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Probable or Definite ALS

Exclusion criteria

Exclusion criteria: Patients where CSF cannot be done

Design outcomes

Secondary

MeasureTime frame
Comparison of CSF levels with plasma levels of heavy metals in patients with ALSTimepoint: 12 months—

Primary

MeasureTime frame
Estimation of Plasma and CSF levels of heavy metals in patients with ALS (amyotrophic lateral sclerosis).Timepoint: 12 months—

Countries

India

Contacts

Public ContactDr Priyanka Samal

All India Institute of Medical Sciences, Bhubaneswar

priyanka_samal87@yahoo.co.in9868981637

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026